TransCode says Phase 1a trial shows 71.4% stable disease rate for TTX-MC138
Updated follow-up data from the ongoing advanced solid tumor trial showed many patients achieved disease stabilization, with some progression-free for a year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.